Physician profile
Evan Leibowitz
NPI 1235194986
$187,668.06
in general payments reported to CMS, 2019-2025
17 companies · $60.68 in 2025
The $60.68 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $71K · 2021: $11K · 2022: $28.23 · 2023: $15.45 · 2024: $76.28 · 2025: $60.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $99,314.95 | 2019-2021 | |
| Lilly USA, LLC | $20,192.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $20,056.77 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $18,834.40 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $16,363.74 | 2019-2021 | |
| Janssen Biotech, INC. | $8,193.45 | 2019-2024 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $4,014.07 | 2019-2021 | |
| Amgen INC. | $195.94 | 2020-2021 | |
| Abbvie INC. | $178.33 | 2019-2021 | |
| Genentech USA, INC. | $150.04 | 2019 | |
| Heartflow, INC. | $92.89 | 2023-2025 | Ffrct |
| Depuy Synthes Sales INC. | $28.23 | 2022 | |
| Pfizer INC. | $14.52 | 2021 | |
| Genzyme Corporation | $13.43 | 2019 | |
| Hikma Pharmaceuticals USA | $13.16 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $11.84 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.